The US Food and Drug Administration (FDA) has approved Amgen’s Prolia, an injectable treatment for menopausal women with osteoporosis.

Prolia decreases destruction of bone and increases bone mass and strength for osteoporosis patients who have a high risk of fracture.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

FDA approval is based on the three-year, double-blind, placebo-controlled, randomised trial of 7,808 postmenopausal women aged between 60 and 91 years.

The trial showed Prolia reduced the incidence of hip, vertebral and non-vertebral fractures in the subjects.

Serious adverse reactions include hypocalcaemia, serious infections and dermatologic reactions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.